Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

@article{Mossner2016MutationalHI,
  title={Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.},
  author={Maximilian Mossner and J. Jann and Janina Wittig and Florian Nolte and Stephanie Fey and Verena Nowak and Julia Oblaender and Jovita Pressler and Iris Palme and Christina Xanthopoulos and Tobias Boch and Georgia Metzgeroth and Henning Roehl and Stephanie H. Witt and Helene Dukal and Corinna Klein and Steffen Schmitt and Patrick Gel\ss and Uwe- Platzbecker and Ekaterina Balaian and Alice Fabarius and H. BrendanMcMahanandAvrim Blum and Torsten J. Schulze and Manja Meggendorfer and Claudia Haferlach and Andreas Trumpp and Wolf-Karsten Hofmann and Hind Medyouf and Daniel Nowak},
  journal={Blood},
  year={2016},
  volume={128 9},
  pages={1246-59}
}
Clonal evolution is believed to be a main driver for progression of various types of cancer and implicated in facilitating resistance to drugs. However, the hierarchical organization of malignant clones in the hematopoiesis of myelodysplastic syndromes (MDS) and its impact on response to drug therapy remain poorly understood. Using high-throughput sequencing of patient and xenografted cells, we evaluated the intratumoral heterogeneity (n= 54) and reconstructed mutational trajectories (n = 39… CONTINUE READING